AD	Alzheimer’s disease
AGE	advanced glycation end-product
AGE-R1/R2/R3	advanced glycation end-product receptor 1/2/3
ALE	advanced lipoxidation end-product
CAD	coronary artery disease
CEL	Nε-(1-carboxyethyl)lysine
CeVD	cerebrovascular disease
CHD	coronary heart disease
CHF	chronic heart failure
CKD	chronic kidney disease
CMA	N7–(carboxymethyl)arginine
CML	Nε-(carboxymethyl)lysine
CVD	cardiovascular disease
dAGE	dietary advanced glycation end-product
FEEL-1/2	fascilin, EGF-like, laminin-type EGF-like and link domain-containing scavenger receptor-1/-2
GOLD	glyoxyl-derived lysine dimer
GSP	Glucosepane
HA	hyaluronic acid
HARE	hyaluronic acid receptor for endocytosis (Stab2)
HbA1c	glycated hemoglobin
LSRD	lifestyle-related disease
MG-H1	methylglyoxal-hydroimidazolone
NAFLD	non-alcoholic fatty liver disease
NASH	non-alcoholic steatohepatitis
OST	N-oligosaccharyl transferase
PAD	peripheral artery disease
PD	Parkinson’s disease
RAGE	receptor for advanced glycation end-product
RNS	reactive nitrogen species
ROS	reactive oxygen species
SAF	skin autofluorescence
SEC	sinusoidal endothelial cell
SR	scavenger receptor
sRAGE	soluble receptor for advanced glycation end-product
Stab1/2	stabilin-1/-2
TAGE	toxic advanced glycation end-product
TIM-1	TNO gastrointestinal in vitro model